drugset / Trial / NCT01366287

A Study Of PF-03882845 Absorption In Healthy Volunteers Given Orally As Tablet Versus Suspension Formulations And Effect Of Food On Its Absorption

NCT01366287

Phase 1 Completed 12 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

The primary purpose of this study is to estimate the relative bioavailability and food effect of a PF-03882845 tablet as compared to a suspension formulation used in previous clinical studies.

Timeline

Start
2011-01
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-03882845 Small molecule 25 mg Oral